Carla Torre
YOU?
Author Swipe
View article: Real-World Data Included in Post-authorisation Measures: A Case Study of Approved Advanced Therapy Medicinal Products in the European Union between 2013 and 2024
Real-World Data Included in Post-authorisation Measures: A Case Study of Approved Advanced Therapy Medicinal Products in the European Union between 2013 and 2024 Open
View article: Strengthening Outbreak Detection in Africa to Achieve the 7-1-7 Global Framework: Challenges and Opportunities
Strengthening Outbreak Detection in Africa to Achieve the 7-1-7 Global Framework: Challenges and Opportunities Open
Objectives Timely detection of infectious disease outbreaks is essential to limit health, social, and economic impacts, yet diagnostic and surveillance gaps persist across Africa. This review applies the 7-1-7 global target framework—detec…
View article: Introduction of Biopharmaceuticals in Europe: A Cross-Sectional Study of Early Diffusion Patterns and Data Availability
Introduction of Biopharmaceuticals in Europe: A Cross-Sectional Study of Early Diffusion Patterns and Data Availability Open
View article: Update on the role of bone turnover markers in the diagnosis and management of osteoporosis: a consensus paper from The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), International Osteoporosis Foundation (IOF), and International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)
Update on the role of bone turnover markers in the diagnosis and management of osteoporosis: a consensus paper from The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), International Osteoporosis Foundation (IOF), and International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Open
View article: Treatment of Osteoporosis and Osteoarthritis in the Oldest Old
Treatment of Osteoporosis and Osteoarthritis in the Oldest Old Open
View article: Patterns of outpatient proton‒pump inhibitors use among older adults in a duplicative health system: comparing public and private prescribing
Patterns of outpatient proton‒pump inhibitors use among older adults in a duplicative health system: comparing public and private prescribing Open
View article: Impact of dementia and mild cognitive impairment on bone health in older people
Impact of dementia and mild cognitive impairment on bone health in older people Open
Mild cognitive impairment, dementia and osteoporosis are common diseases of ageing and, with the increasingly ageing global population, are increasing in prevalence. These conditions are closely associated, with shared risk factors, common…
View article: Proton-pump inhibitor use in older adults: Public vs. Private Prescribing in Portugal
Proton-pump inhibitor use in older adults: Public vs. Private Prescribing in Portugal Open
Background Proton pump inhibitors (PPI) are frequently overprescribed, posing challenges to patients and healthcare systems. In Portugal, the publicly funded National Health Service (NHS) provides universal coverage and reimburses the cost…
View article: COVID-19 pandemic and the consumption of self-care products for pediculosis capitis in Portugal: an interrupted time-series analysis
COVID-19 pandemic and the consumption of self-care products for pediculosis capitis in Portugal: an interrupted time-series analysis Open
View article: Leveraging patient experience data to guide medicines development, regulation, access decisions and clinical care in the EU
Leveraging patient experience data to guide medicines development, regulation, access decisions and clinical care in the EU Open
Patient experience data (PED), provided by patients/their carers without interpretation by clinicians, directly capture what matters more to patients on their medical condition, treatment and impact of healthcare. PED can be collected thro…
View article: Medicines for an aging population: The <scp>EMA</scp> perspective and policies
Medicines for an aging population: The <span>EMA</span> perspective and policies Open
The European Medicines Agency adopted their Geriatric Medicines Strategy more than a decade ago. The strategy aims at elucidating the evidence basis for marketing authorization of new medicines which will be used in the older population, a…
View article: Tumor mutational burden in colorectal cancer: Implications for treatment
Tumor mutational burden in colorectal cancer: Implications for treatment Open
Although immune checkpoint inhibitors have revolutionized the treatment of several advanced solid cancers, in colorectal cancer, the transformative benefit of these innovative medicines is currently limited to those with deficient mismatch…
View article: Spanish Abstracts for Volume 35, Issue 2, 2023
Spanish Abstracts for Volume 35, Issue 2, 2023 Open
Antecedentes: El tratamiento combinado de ácido zoledrónico (ZOL, zoledronic acid) e inhibidor de la aromatasa (AI, aromatase inhibitor) reduce el riesgo de metástasis ósea (BM, bone metàstasis) y mejora la supervivencia global (OS, overal…
View article: Trends in orphan medicinal products approvals in the European Union between 2010–2022
Trends in orphan medicinal products approvals in the European Union between 2010–2022 Open
Background Over the last twenty years of orphan drug regulation in Europe, the regulatory framework has increased its complexity, with different regulatory paths and tools engineered to facilitate the innovation and accelerate approvals. R…
View article: Inclusion of functional measures and frailty in the development and evaluation of medicines for older adults
Inclusion of functional measures and frailty in the development and evaluation of medicines for older adults Open
The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) E7, the guidance for the conduct of clinical trials in people older than age 65 years, dates from 1994. Since then, the inclusion…
View article: Factors associated with underreporting of adverse drug reactions by patients: a systematic review
Factors associated with underreporting of adverse drug reactions by patients: a systematic review Open
Background Spontaneous reporting is the most used method to monitor post-marketing safety information. Although patient involvement in spontaneous reporting has increased overtime, little is known about factors associated with patients’ ad…
View article: Treatment Advances in Sepsis and Septic Shock: Modulating Pro- and Anti-Inflammatory Mechanisms
Treatment Advances in Sepsis and Septic Shock: Modulating Pro- and Anti-Inflammatory Mechanisms Open
Sepsis is currently defined as a life-threatening organ dysfunction caused by a dysregulated host response to infection, and it affects over 25 million people every year. Even more severe, septic shock is a subset of sepsis defined by pers…
View article: COVID-19 pandemic and the quality of antibiotic use in primary care: an interrupted time-series study
COVID-19 pandemic and the quality of antibiotic use in primary care: an interrupted time-series study Open
The coronavirus disease-19 pandemic and the related public health mitigation measures have impacted the transmission of infectious diseases; however, their impact on the use of antibacterials has not yet been extensively evaluated. This st…
View article: A review of patient-reported outcomes used for regulatory approval of oncology medicinal products in the European Union between 2017 and 2020
A review of patient-reported outcomes used for regulatory approval of oncology medicinal products in the European Union between 2017 and 2020 Open
Introduction Cancer and corresponding available treatments are associated with substantial symptoms and functional limitations. In this context, collection of patient-reported outcomes (PRO) in clinical trials gained special interest and i…
View article: Burnout in the Pharmaceutical Activity: The Impact of COVID-19
Burnout in the Pharmaceutical Activity: The Impact of COVID-19 Open
Importance Pharmacists are among the healthcare professionals involved in the response to the COVID-19 pandemic, maintaining essential services. In the context of restrictions and reorganization of human resources, as a result of policies …
View article: A review of the continuous professional development system for pharmacists
A review of the continuous professional development system for pharmacists Open
View article: Implementation and Access to Pre-exposure Prophylaxis for Human Immunodeficiency Virus by Men Who Have Sex With Men in Europe
Implementation and Access to Pre-exposure Prophylaxis for Human Immunodeficiency Virus by Men Who Have Sex With Men in Europe Open
Pre-exposure prophylaxis (PrEP) is a significant public health intervention with proven efficacy and safety in the prevention of human immunodeficiency virus (HIV) infection, which has taken a considerable amount of time to reach Europe in…
View article: Overtreatment and undertreatment in a sample of elderly people with diabetes
Overtreatment and undertreatment in a sample of elderly people with diabetes Open
Aims In older adults with type 2 diabetes (T2D), overtreatment remains prevalent and undertreatment ignored. The main objective is to estimate the prevalence and examine factors associated with potential overtreatment and undertreatment Me…
View article: Scientific Advances in Diabetes: The Impact of the Innovative Medicines Initiative
Scientific Advances in Diabetes: The Impact of the Innovative Medicines Initiative Open
Diabetes Mellitus is one of the World Health Organization's priority diseases under research by the first and second programmes of Innovative Medicines Initiative, with the acronyms IMI1 and IMI2, respectively. Up to October of 2019, 13 pr…
View article: Burnout in the Pharmaceutical Activity: The Impact of COVID-19
Burnout in the Pharmaceutical Activity: The Impact of COVID-19 Open
View article: Pharmaceutical Practice: Health & Medicines Information
Pharmaceutical Practice: Health & Medicines Information Open
Accepted abstracts under the theme: HEALTH & MEDICINES INFORMATION (n=22)
View article: Polypharmacy, potentially serious clinically relevant drug‐drug interactions, and inappropriate medicines in elderly people with type 2 diabetes and their impact on quality of life
Polypharmacy, potentially serious clinically relevant drug‐drug interactions, and inappropriate medicines in elderly people with type 2 diabetes and their impact on quality of life Open
The aim of the study is to investigate the patterns of polypharmacy, clinical‐relevant drug‐drug interactions (DDIs), and potentially inappropriate medicines (PIMs), and whether polypharmacy, potential serious clinically‐relevant DDIs, or …
View article: Effect of Different Methods for Estimating Persistence and Adherence to New Glucose-Lowering Drugs: Results of an Observational, Inception Cohort Study in Portugal
Effect of Different Methods for Estimating Persistence and Adherence to New Glucose-Lowering Drugs: Results of an Observational, Inception Cohort Study in Portugal Open
Purpose: Several methods have been developed for assessing medication-taking behavior; understanding the determinants and variability in estimates obtained is crucial in interpreting results. We estimated persistence and adherence levels t…
View article: Do Rational Use Meet Reality in a Country under Financial Assistance Program for Cost-saving Expenditures? The Two Sides of the Portuguese Coin
Do Rational Use Meet Reality in a Country under Financial Assistance Program for Cost-saving Expenditures? The Two Sides of the Portuguese Coin Open
BackgroundThe Memorandum of Understanding (MoU) signed in 2011, between the Portugal (PT) and the European Commission, International Monetary Fund and the European Central Bank, imposed the establishment and monitoring of several prescribi…
View article: Intensive Monitoring Studies for Assessing Medicines: A Systematic Review
Intensive Monitoring Studies for Assessing Medicines: A Systematic Review Open
Introduction: Intensive monitoring (IM) is one of the methods of post-marketing active surveillance based upon event monitoring, which has received interest in the current medicines regulatory landscape. For a specific period of tim…